Welcome to BioSeeker Group!

Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?

Additional Information

Published Date May 28, 2009
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 373
PDF Fact Sheet View Fact Sheet for the report Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize? in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

$2,450.00

Quick Overview

This report is an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?.

    To find out more about Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Alternative binding peptide molecules, derived from combinatorial scaffold libraries, are now challenging traditional antibodies. This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant.

This report includes defined and up to date development strategies for 92 cancer therapeutic peptide drugs (>170 projects) within the portfolio of 70 investigators, from Ceased to Marketed. In total the report assesses 30 different cancer indications. The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning by:

- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report will also be an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

1 Executive Summary 3
2 About Cancer Highlights 4
3 Methodologies 6
4 Table of Contents 8
4.1 List of Figures 14
4.2 List of Tables 14
5 Introduction 20
5.1 The Scope of this Report 20
5.2 The Competitive Advantage and Disadvantage of Peptide Drugs 24
5.3 Definitions 25
5.4 Abbreviations 25
6 Consider the Therapeutic Target for the Highest Therapeutic Outcome and Return on Investment 26
6.1.1 Chaperone Activity Targets 28
6.1.2 Chemokine Activity Targets 30
6.1.3 DNA Binding Targets 32
6.1.4 DNA topoisomerase activity Targets 33
6.1.5 G-protein Coupled Receptor Activity Targets 34
6.1.6 Growth Factor Activity Targets 48
6.1.7 Heat Shock Protein Activity Targets 49
6.1.8 Hormone Activity Targets 50
6.1.9 Kinase Activity Targets 51
6.1.10 Kinase Binding Targets 53
6.1.11 Kinase Regulator Activity Targets 54
6.1.12 Ligand-dependent Nuclear Receptor Activity Targets 55
6.1.13 Metallopeptidase Activity Targets 58
6.1.14 Molecular Function Unknown Targets 62
6.1.15 Oxidoreductase Activity Targets 65
6.1.16 Peptide Hormone Targets 66
6.1.17 Protease Inhibitor Activity Targets 68
6.1.18 Protein Binding Targets 69
6.1.19 Protein Serine/Threonine Kinase Activity Targets 70
6.1.20 Protein Tyrosine/Serine/Threonine Phosphatase Activity Targets 74
6.1.21 Protein-Tyrosine Kinase Activity Targets 75
6.1.22 Protein-Tyrosine Kinase Activity Targets 77
6.1.23 Receptor Activity Targets 78
6.1.24 Receptor Signaling Complex Scaffold Activity Targets 91
6.1.25 RNA Binding Targets 95
6.1.26 RNA-directed DNA Polymerase Activity Targets 96
6.1.27 Serine-type Peptidase Activity Targets 97
6.1.28 Structural Molecule Activity Targets 99
6.1.29 T cell Receptor Activity Targets 100
6.1.30 Transcription Factor Activity Targets 101
6.1.31 Transcription Regulator Activity Targets 104
6.1.32 Transferase Activity Targets 105
6.1.33 Transmembrane Receptor Activity Targets 106
6.1.34 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 108
6.1.35 Ubiquitin-specific Protease Activity Targets 115
6.2 The Cancer Genome Project and Peptide Drug Targets 116
6.2.1 Peptide Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 116
6.3 Structure-based Drug Design of Anti-Cancer Peptides is Stimulated by Available Structure Data on Biological Targets 118
6.4 Target-Target Interactions among Identified Peptide Targets 121
6.5 The Drug-Target Interactome 125
6.6 Protein Expression Levels of Identified Drug Targets of Anti-Cancer Peptide Drugs 128
6.7 Pathway Analysis of Anti-Cancer Peptide Drug Targets 131
7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Profiles Identified in the Cancer Therapeutic Peptide Pipeline? 152
7.1 Marketed: New and Unique Target Profiles in the Cancer Therapeutic Peptide Pipeline 156
7.2 Phase III Clinical Development: New and Unique Target Profiles in the Cancer Therapeutic Peptide Pipeline 157
7.3 Phase II Clinical Development: New and Unique Target Profiles in the Cancer Therapeutic Peptide Pipeline 158
7.4 Phase I Clinical Development: New and Unique Target Profiles in the Cancer Therapeutic Peptide Pipeline 160
7.5 Preclinical Development: New and Unique Target Profiles in the Cancer Therapeutic Peptide Pipeline 162
7.6 Development Stage Outline of All Cancer Therapeutic Peptides by Target Profiles 165
8 Selecting Cancer Indication for Therapeutic Peptides 174
8.1 Acute Myelogenous Leukemia 176
8.2 Benign Prostatic Hyperplasia 177
8.3 Bladder Cancer 177
8.4 Brain Cancer 178
8.5 Breast Cancer 178
8.6 Carcinoid 181
8.7 Chronic Myelogenous Leukemia 181
8.8 Colorectal Cancer 182
8.9 Gastrointestinal Cancer (general) 184
8.10 Gastrointestinal Stomach Cancer 184
8.11 Head and Neck Cancer 185
8.12 Liver Cancer 185
8.13 Lung Cancer (general) 186
8.14 Lymphoma (general) 187
8.15 Melanoma 187
8.16 Mesothelioma 188
8.17 Myelodysplastic Syndrome 188
8.18 Myeloma 189
8.19 Myoma 191
8.20 Neuroblastoma 191
8.21 non-Hodgkin’s Lymphoma 191
8.22 Non-small Cell Lung Cancer 192
8.23 Ovarian Cancer 193
8.24 Pancreatic Cancer 194
8.25 Prostate Cancer 195
8.26 Renal Cancer 198
8.27 Sarcoma (general) 198
8.28 Small Cell Lung Cancer 199
8.29 Soft Tissue Sarcoma 199
8.30 Unspecified Cancer Indication 200
9 Portfolio Planning: Competitive Benchmarking of Cancer Therapeutic Peptide Pipeline by Investigator 202
9.1 Abbott 204
9.2 Acceleron Pharma 208
9.3 Aeterna Zentaris 210
9.4 Affymax 215
9.5 Ambrilia Biopharma 217
9.6 AplaGen Biopharmaceuticals 219
9.7 ApopLogic Pharmaceuticals 221
9.8 Apthera 224
9.9 Ardana 226
9.10 Attenuon 230
9.11 AVI BioPharma 232
9.12 Baxter International 234
9.13 BioAlliance Pharma 237
9.14 Biokine Therapeutics 239
9.15 CanBas 241
9.16 Cancer Innovations 243
9.17 Cancer Research Technology 245
9.18 Celecure 248
9.19 Celldex Therapeutics 250
9.20 Chemokine Therapeutics 252
9.21 Compugen 254
9.22 Cyclacel 256
9.23 Dendreon 258
9.24 DOR BioPharma 260
9.25 Enkam Pharmaceuticals 263
9.26 EntreMed 265
9.27 GlaxoSmithKline 268
9.28 GP Pharm 270
9.29 ImmunoCellular Therapeutics 274
9.30 Immunotope 276
9.31 ImmuPharma 278
9.32 Indevus 280
9.33 Innovive 283
9.34 Johnson & Johnson 286
9.35 Mediolanum 290
9.36 MolMed 293
9.37 Nektar Therapeutics 295
9.38 Nemod Biotherapeutics 298
9.39 Nidus Laboratories 300
9.40 Norwood Abbey 302
9.41 Novartis 305
9.42 OncoTherapy Science 307
9.43 Oncothyreon 309
9.44 Pepscan Systems 312
9.45 PharmaGap 314
9.46 Pharmexa 316
9.47 QLT 319
9.48 Raptor Pharmaceutical 322
9.49 Receptor BioLogix 325
9.50 SciClone Pharmaceuticals 328
9.51 Shire 331
9.52 Spectrum Pharmaceuticals 334
9.53 Thallion Pharmaceuticals 336
9.54 Therion Biologics 338
9.55 Theryte 340
9.56 Tigris Pharmaceuticals 342
9.57 Unigene 344
9.58 United Biomedical 347
9.59 Vaxil BioTherapeutics 349
9.60 Vaxon Biotech 351
9.61 Voyager Pharmaceutical 353
9.62 Xigen 356
9.63 Zelos Therapeutics 358
9.64 Zensun 360
9.65 Non-Industrial sources 362
10 Disclaimer 367
11 Drug Index 368
12 Company Index 371

4.1 List of Figures
Figure 1: Overall Breakdown of the Included Cancer Therapeutic Peptide Pipeline by Cancer Indication and Stage of Development 21
Figure 2: Visualization of Target-Target Interactions Among Peptide Drug Targets 124
Figure 3: The Drug-Protein Interactome of Peptide Drugs 127

4.2 List of Tables
Table 1: Competitive Pressure Force Among Cancer Therapeutic Peptides 20
Table 2: Overview of Drug Target Profile Themes 26
Table 3: Drug Targets of Peptide Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 117
Table 4: Identity of Peptide Drug Targets with Available Biological Structures 119
Table 5: Number of Target-Target Interactions among Peptide Drug Targets 121
Table 6: Drug-Protein Interactome Clusters 125
Table 7: Peptide Drug Targets with Available Protein Expression Profiles 128
Table 8: Pathway Summary 131
Table 9: Peptide Drug Targets without any Identified Assigned Pathways 131
Table 10: Pathway Profile According to BioCarta of Peptide Drug Targets 132
Table 11: Pathway Profile According to KEGG of Peptide Drug Targets 140
Table 12: Pathway Profile According to NetPath of Peptide Drug Targets 150
Table 13: Number of Drug Target Profiles of Peptide Drugs by the Highest Developmental Stage and Uniqueness 152
Table 14: Terminally Ceased Drug Target Profiles of Cancer Therapeutic Peptides 153
Table 15: Top 5 Competitive Peptide Drug Target Profiles 153
Table 16 New and Unique Target Profiles of Peptide Drugs on the Market 156
Table 17: New and Unique Target Profiles of Peptide Drugs in Phase III Clinical Development 157
Table 18: New and Unique Target Profiles of Peptide Drugs in Phase II Clinical Development 158
Table 19 New and Unique Target Profiles of Peptide Drugs in Phase I Clinical Development 160
Table 20: New and Unique Target Profiles of Peptide Drugs in Preclinical Development 163
Table 21: The Progression, Maturity and Competitive Comparison of Cancer Therapeutic Peptide Target Profiles in Development 165
Table 22: Competitive Summary of Peptide Drugs by Cancer Indication 174
Table 23: Drug Target Profiles of Peptides for the Treatment of Acute Myelogenous Leukemia According to Developmental Stage of Peptide 176
Table 24: Drug Target Profiles of Peptides for the Treatment of Benign Prostatic Hyperplasia According to Developmental Stage of Peptide 177
Table 25: Drug Target Profiles of Peptides for the Treatment of Bladder Cancer According to Developmental Stage of Peptide 177
Table 26: Drug Target Profiles of Peptides for the Treatment of Brain Cancer According to Developmental Stage of Peptide 178
Table 27: Drug Target Profiles of Peptides for the Treatment of Breast Cancer According to Developmental Stage of Peptide 179
Table 28: Drug Target Profiles of Peptides for the Treatment of Carcinoid According to Developmental Stage of Peptide 181
Table 29: Drug Target Profiles of Peptides for the Treatment of Chronic Myelogenous Leukemia According to Developmental Stage of Peptide 182
Table 30: Drug Target Profiles of Peptides for the Treatment of Colorectal Cancer According to Developmental Stage of Peptide 182
Table 31: Drug Target Profiles of Peptides for the Treatment of Gastrointestinal Cancer (general) According to Developmental Stage of Peptide 184
Table 32: Drug Target Profiles of Peptides for the Treatment of Gastrointestinal Stomach Cancer According to Developmental Stage of Peptide 184
Table 33: Drug Target Profiles of Peptides for the Treatment of Head and Neck Cancer According to Developmental Stage of Peptide 185
Table 34: Drug Target Profiles of Peptides for the Treatment of Liver Cancer According to Developmental Stage of Peptide 186
Table 35: Drug Target Profiles of Peptides for the Treatment of Lung Cancer (general) According to Developmental Stage of Peptide 186
Table 36: Drug Target Profiles of Peptides for the Treatment of Lymphoma (general) According to Developmental Stage of Peptide 187
Table 37: Drug Target Profiles of Peptides for the Treatment of Melanoma According to Developmental Stage of Peptide 187
Table 38: Drug Target Profiles of Peptides for the Treatment of Mesothelioma According to Developmental Stage of Peptide 188
Table 39: Drug Target Profiles of Peptides for the Treatment of Myelodysplastic Syndrome According to Developmental Stage of Peptide 189
Table 40: Drug Target Profiles of Peptides for the Treatment of Myeloma According to Developmental Stage of Peptide 189
Table 41: Drug Target Profiles of Peptides for the Treatment of Myoma According to Developmental Stage of Peptide 191
Table 42: Drug Target Profiles of Peptides for the Treatment of Neuroblastoma According to Developmental Stage of Peptide 191
Table 43: Drug Target Profiles of Peptides for the Treatment of non-Hodgkin’s Lymphoma According to Developmental Stage of Peptide 191
Table 44: Drug Target Profiles of Peptides for the Treatment of Non-small Cell Lung Cancer According to Developmental Stage of Peptide 192
Table 45: Drug Target Profiles of Peptides for the Treatment of Ovarian Cancer According to Developmental Stage of Peptide 193
Table 46: Drug Target Profiles of Peptides for the Treatment of Pancreatic Cancer According to Developmental Stage of Peptide 194
Table 47: Drug Target Profiles of Peptides for the Treatment of Prostate Cancer According to Developmental Stage of Peptide 196
Table 48: Drug Target Profiles of Peptides for the Treatment of Renal Cancer According to Developmental Stage of Peptide 198
Table 49: Drug Target Profiles of Peptides for the Treatment of Sarcoma (general) According to Developmental Stage of Peptide 198
Table 50: Drug Target Profiles of Peptides for the Treatment of Small Cell Lung Cancer According to Developmental Stage of Peptide 199
Table 51: Drug Target Profiles of Peptides for the Treatment of Soft Tissue Sarcoma According to Developmental Stage of Peptide 199
Table 52: Drug Target Profiles of Peptides for the Treatment of Not Specified Cancer Indication According to Developmental Stage of Peptide 200
Table 53: Abbott’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 204
Table 54: Acceleron Pharma’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 208
Table 55: Aeterna Zentaris’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 210
Table 56: Affymax’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 215
Table 57: Ambrilia Biopharma’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 217
Table 58: AplaGen Biopharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 219
Table 59: ApopLogic Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 221
Table 60: Apthera’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 224
Table 61: Ardana’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 226
Table 62: Attenuon’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 230
Table 63: AVI BioPharma’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 232
Table 64: Baxter International’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 234
Table 65: BioAlliance Pharma’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 237
Table 66: Biokine Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 239
Table 67: CanBas’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 241
Table 68: Cancer Innovations’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 243
Table 69: Cancer Research Technology’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 245
Table 70: Celecure’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 248
Table 71: Celldex Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 250
Table 72: Chemokine Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 252
Table 73: Compugen’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 254
Table 74: Cyclacel’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 256
Table 75: Dendreon’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 258
Table 76: DOR BioPharma’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 260
Table 77: Enkam Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 263
Table 78: EntreMed’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 265
Table 79: GlaxoSmithKline’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 268
Table 80: GP Pharm’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 270
Table 81: ImmunoCellular Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 274
Table 82: Immunotope’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 276
Table 83: ImmuPharma’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 278
Table 84: Indevus’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 280
Table 85: Innovive’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 283
Table 86: Johnson & Johnson’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 286
Table 87: Mediolanum’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 290
Table 88: MolMed’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 293
Table 89: Nektar Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 295
Table 90: Nemod Biotherapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 298
Table 91: Nidus Laboratories’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 300
Table 92: Norwood Abbey’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 302
Table 93: Novartis’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 305
Table 94: OncoTherapy Science’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 307
Table 95: Oncothyreon’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 309
Table 96: Pepscan Systems’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 312
Table 97: PharmaGap’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 314
Table 98: Pharmexa’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 316
Table 99: QLT’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 319
Table 100: Raptor Pharmaceutical’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 322
Table 101: Receptor BioLogix’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 325
Table 102: SciClone Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 328
Table 103: Shire’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 331
Table 104: Spectrum Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 334
Table 105: Thallion Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 336
Table 106: Therion Biologics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 338
Table 107: Theryte’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 340
Table 108: Tigris Pharmaceuticals’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 342
Table 109: Unigene’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 344
Table 110: United Biomedical’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 347
Table 111: Vaxil BioTherapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 349
Table 112: Vaxon Biotech’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 351
Table 113: Voyager Pharmaceutical’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 353
Table 114: Xigen’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 356
Table 115: Zelos Therapeutics’ Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 358
Table 116: Zensun’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 360
Table 117: Non-industrial source’s Included Cancer Therapeutic Peptide Pipeline Composition and Competitive Fall-Out 362

This report covers in-depth the following investigators:
Abbott
Acceleron Pharma
Aeterna Zentaris
Affymax
Ambrilia Biopharma
AplaGen Biopharmaceuticals
ApopLogic Pharmaceuticals
Apthera
Ardana
Attenuon
AVI BioPharma
Baxter International
BioAlliance Pharma
Biokine Therapeutics
CanBas
Cancer Innovations
Cancer Research Technology
Celecure
Celldex Therapeutics
Chemokine Therapeutics
Compugen
Cyclacel
Dendreon
DOR BioPharma
Enkam Pharmaceuticals
EntreMed
GlaxoSmithKline
GP Pharm
ImmunoCellular Therapeutics
Immunotope
ImmuPharma
Indevus
Innovive
Johnson & Johnson
MD Anderson Cancer Center
Medical College of Wisconsin
Mediolanum
MolMed
Nektar Therapeutics
Nemod Biotherapeutics
Nidus Laboratories
Norwood Abbey
Novartis
OncoTherapy Science
Oncothyreon
Pepscan Systems
PharmaGap
Pharmexa
QLT
Raptor Pharmaceutical
Receptor BioLogix
Sapporo Medical University School of Medicine
SciClone Pharmaceuticals
Shire
Spectrum Pharmaceuticals
Thallion Pharmaceuticals
Therion Biologics
Theryte
Tigris Pharmaceuticals
Unigene
United Biomedical
University of Pittsburgh
University of Siena, Siena
University of Ulm, Ulm
Vaxil BioTherapeutics
Vaxon Biotech
Voyager Pharmaceutical
Xigen
Zelos Therapeutics
Zensun
Includes a total of 92 cancer therapeutic peptide drugs. Some examples are:
ABT-510
ACE-011
ATN-161
CDX-110
cetrorelix acetate
CMLVAX-100
CTCE-9908
deslorelin
E-75
GV-1001
Her-2/Neu peptides
histrelin
leuprolide
leuprolide acetate
leuprorelin
ozarelix
pasireotide
Stimuvax
thymalfasin
tigapotide triflutate
TLN-232

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?.
    To find out more about Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize? is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


The Drug Target Atlas of Protein Kinase Inhibitors in Oncology
This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new protein kinase inhibitor drugs in oncology. Learn More


Cancer Vaccines: Aim and Shoot
This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. Learn More

Other selected research from the 'Oncology' category:


Protein Kinase Therapeutics in Oncology - Where to Commercialize?
This report is an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More


Targeting Immune Checkpoints in Cancer Immunotherapy Drug Pipeline Update
BioSeeker Group have identified 120 companies plus partners who are today developing 227 immune checkpoints drugs in 835 developmental projects in cancer across 71 different targets. In addition, there are 4 suspended drugs and another 19 drugs where development has been ceased. Learn More

Other selected research from the 'Biologicals' category:


Peptides in Oncology Drug Pipeline Update
BioSeeker Group have identified 340 companies plus partners who are today developing 356 peptide drugs in 778 developmental projects in cancer across 252 different targets. In addition, there are 4 suspended drugs and another 148 drugs where development has been ceased. Learn More


Cancer Vaccines: From First-in-Class to Best-in-Class?
In-depth pipeline analytics of cancer vaccine drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, Indication expansion opportunities and much more Learn More